Format

Send to

Choose Destination
See comment in PubMed Commons below
Best Pract Res Clin Endocrinol Metab. 2009 Oct;23(5):597-606. doi: 10.1016/j.beem.2009.05.006.

Pituitary tumours: TSH-secreting adenomas.

Author information

1
Department of Medical Sciences, University of Milan, Fondazione Policlinico IRCCS, Padiglione Granelli, Via F. Sforza 35, 20122 Milan, Italy. paolo.beckpeccoz@unimi.it

Abstract

Thyrotropin-secreting pituitary adenomas (TSHomas) are a rare cause of hyperthyroidism and account for less than 2% of all pituitary adenomas. In the last years, the diagnosis has been facilitated by the routine use of ultra-sensitive TSH immunometric assays. Failure to recognise the presence of a TSHoma may result in dramatic consequences, such as improper thyroid ablation that may cause the pituitary tumour volume to further expand. The diagnosis mainly rests on dynamic testing, such as T3 suppression tests and TRH, which are useful in differentiating TSHomas from the syndromes of thyroid hormone resistance. The first therapeutical approach to TSHomas is the pituitary neurosurgery. The medical treatment of TSHomas mainly rests on the administration of somatostatin analogues, such as octreotide and lanreotide, which are effective in reducing TSH secretion in more than 90% of patients with consequent normalisation of FT4 and FT3 levels and restoration of the euthyroid state.

PMID:
19945025
DOI:
10.1016/j.beem.2009.05.006
[Indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments

    Supplemental Content

    Full text links

    Icon for Elsevier Science
    Loading ...
    Support Center